> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-109/
- Published: 2018-06-03T12:00:00.000Z
- Updated: 2026-09-15T00:10:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141595

**Amneal** has acquired **Gemini Laboratories**, a company focused on branded pharmaceuticals, for $117 million. Gemini’s lead product is Unithroid to treat hypothyroidism. Amneal also entered into a licensing agreement for the U.S. market with Spanish company **MabXience SL** for its biosimilar candidate for **Roche**’s Avastin (bevacizumab).

**Surmodics** has reached an agreement with **Embolitech** to acquire an innovative thrombectomy platform technology and related intellectual property with broad potential peripheral vascular applications. Under the agreement, Surmodics will pay $5 million up front, and additional amounts related to various regulatory milestones. The Embolitech technology platform is designed to remove difficult, organized (hard) blood clots.

**Laborie Medical** has completed its acquisition of **Cogentix Medical**. Under the transaction, Laborie obtains the rights to Urgent PC Neuromodulation System for overactive bladder and Macroplastique Injectable, a soft-tissue bulking agent used to treat female stress urinary incontinence.

**Tekni-Plex** has acquired **Dunn Industries**, a manufacturer of specialty extrusion tubing for medical device applications. Dunn also has expertise in a wide range of thermoplastic materials and offers both standard and custom-engineered tubing solutions. Its product line is also a complementary addition to the microextrusion tubing manufactured by Tekni-Plex's **Natvar** business unit.